Author's response to reviews

Title: Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study

Authors:

Weerawat Manosuthi (idweerawat@yahoo.com)
Preecha Tantanathip (preecha@moph.co.th)
Wisit Prasithisirikul (drwisit@cscoms.com)
Sirirat Likanonsakul (siratlik@health.moph.go.th)
Somnuek Sungkanuparph (ssungkanuparph@yahoo.com)

Version: 2 Date: 25 June 2008

Author's response to reviews: see over
Dear Editor,

Enclosed please find the attached file of a manuscript entitled “Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Previous Received of Rifampicin: A 144-week Prospective Study”, an original article for consideration to publish in BMC Medicine. The interesting point in the present study is that this study demonstrated the long-term clinical response of stavudine, lamivudine and nevirapine among advanced HIV-infected patients in a resource-limited setting. I believe that the results from the present study may be additional information for the physicians who care HIV-infected patients in the resource-constrained countries.

The current information to authors has been read and followed. This article has never been published elsewhere or submitted simultaneously for publication.

Corresponding author and person dealing with paper publication is:

Weerawat Manosuthi, M.D.
Bamrasnaradura Infectious Diseases Institute
Ministry of Public Health
Tiwanon Road, Nonthaburi, 11000, Thailand
Tel. (66) 2 2-1-1581, Fax. (66) 2 201-2107

e-mail address: drweerawat@hotmail.com, idweerawat@yahoo.com

Yours sincerely,

Weerawat Manosuthi, M.D.